Translate

Monday, June 17, 2019

thumbnail

IOVA Iovance Biotherapeutics, Inc. gains 62% Jun 4, 2019

Lion Biotechnologies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of patients with refractory metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health for technologies relating to autologous TIL adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder, and HPV-positive cancers; cooperative research and development agreement with the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient's TIL, as well as for the treatment of cervical, head and neck, lung, bladder, and breast cancer; and manufacturing services agreement with Lonza Walkersville, Inc. and WuXi Apptech, Inc. to manufacture, package, ship, and handle quality assurance and quality control of clinical trials for TIL products. In addition, it has collaboration and license agreements with Medimmune, Inc. to conduct clinical and preclinical research in immuno-oncology; H. Lee Moffitt Cancer Center and Research Institute to research and develop adoptive TIL cell therapy; and PolyBioCept, AB to develop, manufacture, market, and genetically engineer TIL. The company was formerly known as Genesis Biopharma Inc. and changed its name to Lion Biotechnologies, Inc. in September 2013. Lion Biotechnologies, Inc. was founded in 2007 and is headquartered in New York, New York.http://www.priceseries.com/trade/IOVA-Iovance-Biotherapeutics-Inc-stock-gains-62-percent-a-Trade-Record-by-priceSeries-2019051520190604.html
thumbnail

AU AngloGold Ashanti Ltd. gains 17% Jun 4, 2019

AngloGold Ashanti Limited operates as a gold mining and exploration company. The company also produces silver, uranium oxide, copper, and sulphuric acid. Its portfolio includes 17 mines in South Africa, Continental Africa, Australasia, and the Americas. AngloGold Ashanti Limited was founded in 1944 and is headquartered in Johannesburg, South Africa.http://www.priceseries.com/trade/AU-AngloGold-Ashanti-Ltd-stock-gains-17-percent-a-Trade-Record-by-priceSeries-2019052920190604.html

Friday, June 14, 2019

thumbnail

DGAZ 3X Inverse Natural Gas ETF gains 21% Jun 14, 2019

The investment seeks to replicate, net of expenses, three times the opposite (inverse) of this GSCI Natural Gas Index ER. The index comprises futures contracts on a single commodity and is calculated according to the methodology of the S&P GSCI Index.http://www.priceseries.com/trade/DGAZ-3X-Inverse-Natural-Gas-ETF-stock-gains-21-percent-a-Trade-Record-by-priceSeries-2019053020190614.html
thumbnail

ARWR Arrowhead Research Corp. gains 21% Jun 14, 2019

Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. Its pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. The company also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreements with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.http://www.priceseries.com/trade/ARWR-Arrowhead-Research-Corp-stock-gains-21-percent-a-Trade-Record-by-priceSeries-2019052120190614.html
thumbnail

ADVM Adverum Biotechnologies, Inc. gains 33% Jun 14, 2019

Avalanche Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company is also developing AVA-201, a product candidate for the prevention of wet AMD; AVA-311 that is in preclinical studies for the treatment of juvenile X-linked retinoschisis, a rare genetic disease of the retina with no approved therapy; and AVA-322 and AVA-323 for the treatment of color vision deficiency. Avalanche Biotechnologies, Inc. has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products. The company was founded in 2006 and is headquartered in Menlo Park, California.http://www.priceseries.com/trade/ADVM-Adverum-Biotechnologies-Inc-stock-gains-33-percent-a-Trade-Record-by-priceSeries-2019051620190614.html

Thursday, June 13, 2019

thumbnail

PDVW pdvWireless, Inc. gains 33% Jun 13, 2019

pdvWireless, Inc. operates as a private wireless communications carrier, and provider of mobile workforce communication and location based solutions in the United States. Its solutions focuses on enhancing the productivity of its customers' field-based workers, and the efficiency of their dispatch and call center operations. The company is deploying and operating dedicated, wide-area, two-way radio networks that offer private push-to-talk (PTT) communications services to primarily dispatch-centric, small and medium-sized businesses in construction, distribution, transportation, field services, waste management, and hospitality industries. It offers DispatchPlus service, which combines pdvConnect, a proprietary suite of mobile communication and workforce management applications with digital network architecture and mobile devices supplied by Motorola Solutions, Inc. The company's solution enables communication and response among field workers and streamlined dispatch operations through exchange of information by prioritizing messages from the field, which can reduce or eliminate wasteful 'on hold time'. In addition, its pdvConnect allows business customers to document field incidents and activities, and to collect operational data and location based information to enhance their operations. The company primarily markets its DispatchPlus service indirectly through Motorola's dealer network and other third-party dealers, with sales, marketing, and advertising support from its internal sales and marketing team. The company was formerly known as Pacific DataVision, Inc. and changed its name to pdvWireless, Inc. in November 2015. pdvWireless, Inc. was incorporated in 1997 and is headquartered in Woodland Park, New Jersey.http://www.priceseries.com/trade/PDVW-pdvWireless-Inc-stock-gains-33-percent-a-Trade-Record-by-priceSeries-2019041620190613.html

Tuesday, June 11, 2019

thumbnail

RNR RenaissanceRe Holdings Ltd. gains 19% Jun 11, 2019

RenaissanceRe Holdings Ltd. together with its subsidiaries, provides reinsurance and insurance coverages and related services in the United States and internationally. The company operates through Property, and Casualty and Specialty segments. The Property segment writes property catastrophe excess of loss reinsurance contracts to insure insurance and reinsurance companies against natural and man-made catastrophes, such as earthquakes, hurricanes, and tsunamis, as well as claims arising from other natural and man-made catastrophes comprising winter storms, freezes, floods, fires, windstorms, tornadoes, explosions, and acts of terrorism; and other property class of products, including proportional reinsurance, property per risk, property reinsurance, and binding facilities and regional U.S. multi-line reinsurance. The Casualty and Specialty segment underwrites various classes of products, such as accident and health, agriculture, automobile liability, aviation, casualty clash, workers' compensation, cyber, employers' liability, energy, environmental liability, marine, medical malpractice, satellite, terrorism, and umbrella or excess casualty. It also offers a range of casualty insurance products through Syndicate 1458, including general liability, medical malpractice, and professional liability. The company distributes its products and services primarily through intermediaries. RenaissanceRe Holdings Ltd. was founded in 1993 and is headquartered in Pembroke, Bermuda.http://www.priceseries.com/trade/RNR-RenaissanceRe-Holdings-Ltd-stock-gains-19-percent-a-Trade-Record-by-priceSeries-2019041020190611.html

TradeVisor Product Review

Review I II III IV

Blog Archive